Who are Linagliptin / Metformin Oral Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sitagliptin phosphate/metformin hydrochloride FDC, Saxagliptin-Metformin XR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/linagliptin-metformin-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Linagliptin / Metformin Oral Tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Linagliptin / Metformin Oral Tablet (Linagliptin / Metformin Oral Tablet) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor / Biguanide combination. Area: Diabetes.

marketed DPP-4 inhibitor / Biguanide combination DPP-4 (dipeptidyl peptidase-4) / AMPK pathway Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Linagliptin / Metformin Oral Tablet (Linagliptin / Metformin Oral Tablet) — Universidad de Guanajuato. Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Linagliptin / Metformin Oral Tablet TARGET	Linagliptin / Metformin Oral Tablet	Universidad de Guanajuato	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
Sitagliptin phosphate/metformin hydrochloride FDC	Sitagliptin phosphate/metformin hydrochloride FDC	Merck Sharp & Dohme LLC	marketed	DPP-4 inhibitor / biguanide combination	DPP-4 enzyme / metformin (AMPK pathway)
Saxagliptin-Metformin XR	Saxagliptin-Metformin XR	Woman's	phase 3	DPP-4 inhibitor / Biguanide combination	DPP-4 enzyme; metformin targets mitochondrial glycerophosphate dehydrogenase and AMPK

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor / Biguanide combination class)

Universidad de Guanajuato · 1 drug in this class
Woman's · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Linagliptin / Metformin Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/linagliptin-metformin-oral-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab